|本期目录/Table of Contents|

[1]邹波涛,胡玉清,尤燕华,等.不同方法治疗血透患者重度继发性甲状旁腺功能亢进对肾性贫血的影响[J].医学研究与战创伤救治(原医学研究生学报),2019,21(02):141-146.[doi:10.3969/j.issn.1672-271X.2019.02.006]
　ZOUBo-tao,HUYu-qing,YOUYan-hua,et al.Effect of different treatments for severe secondary hyperparathyroidism in patients with hemodialysis on renal anemia[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(02):141-146.[doi:10.3969/j.issn.1672-271X.2019.02.006]
点击复制

不同方法治疗血透患者重度继发性甲状旁腺功能亢进对肾性贫血的影响()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第21卷
期数:
2019年02期
页码:
141-146
栏目:
临床研究
出版日期:
2019-03-20

文章信息/Info

Title:
Effect of different treatments for severe secondary hyperparathyroidism in patients with hemodialysis on renal anemia
作者:
邹波涛; 胡玉清; 尤燕华; 李彩凤; 梁萌; 许树根
作者单位：361003 厦门，厦门大学附属成功医院（解放军陆军第七十三集团军医院）肾内科（邹波涛、胡玉清、尤燕华、李彩凤、梁 萌、许树根）
Author(s):
ZOU　Bo-tao;  HU　Yu-qing;  YOU　Yan-hua;  LI　Cai-feng;  LIANG　Meng;  XU　Shu-gen
（Department of Nephrology, the Cheng-gong Affiliated Hospital of Xiamen University/No.73 Army’ Hospital of PLA, Xiamen 361003，Fujian, China）
关键词:
甲状旁腺全切术; 西那卡塞; 血液透析; 继发性甲状旁腺功能亢进; 肾性贫血
Keywords:
total parathyroidectomy;  cinavalcet;  hemodialysis;  secondary hyperparathyroidism;  renal anemia
分类号:
R45
DOI:
10.3969/j.issn.1672-271X.2019.02.006
文献标志码:
A
摘要:
目的　探讨及对比甲状旁腺全切术（T-PTX）及口服西那卡塞治疗血透患者重度继发性甲状旁腺功能亢进（SHPT）对肾性贫血的影响。 方法　回顾性分析2013年4月至2017年2月厦门大学附属成功医院血透合并重度SHPT患者临床资料，行T-PTX治疗者33例作为手术组，口服西那卡塞治疗者22例作为药物组，统计2组患者治疗前、治疗后第1、3、6、12个月的血清全段甲状旁腺素（iPTH）、碱性磷酸酶（ALP）、钙、磷、转铁蛋白饱和度（TSAT）、铁蛋白（SF）、C-反应蛋白（CRP）、白蛋白（Alb）及血红蛋白（Hb）、红细胞压积（Hct）、促红细胞生成素(EPO)用量等数据，并进行分析比较。 结果　手术组iPTH从治疗后第1个月开始，Hb、Hct和EPO用量从第6个月开始优于药物组，差异均有统计学意义（P<0.05）；治疗后第12个月，手术组及药物组iPTH分别下降至（76.2±65.2）pg/mL和（638.9±233.8）pg/mL，Hb分别上升至（115.8±9.3）g/L和（109.5±5.4）g/L，EPO用量分别下降至（94.2±23.7） U/（kg?周）和（153.7±24.8）U/（kg?周），与组内治疗前以及组间比较差异均有统计学意义（P<0.05）。2组患者在治疗前及随访期内的铁贮指标存（TSAT、SF）、炎症指标（CRP）、营养指标（Alb）等组内、组间比较差异均无统计学意义（P>0.05）。手术组不良反应发生率高于药物组（P<0.01）。 结论　治疗血透患者重度SHPT对改善肾性贫血有益，且T-PTX在纠正SHPT及改善贫血方面较西那卡塞效果更好。
Abstract:
Objective　To investigate the effect of total parathyroidectomy (T-PTX) for severe secondary hyperparathyroidism(SHPT)in patients with hemodialysis(HD) on renal anemia, and compared with those treated with Cinavalcet.　Methods　The patients who were maintenance HD with severe SHPT were enrolled into the retrospective case-control study, Thirty-three patients were underwent T-PTX (surgical group) and 22 patients received Cinavalcet treatment in the same period (drug group).The general data of patients in two groups and the changes of relevant indicators such as the serum levels of intact parathyroid hormone (iPTH), alkaline phosphatase(ALP), calcium(Ca), phosphorus(P), hemoglobin(Hb), red cell volume(Hct), transferrin saturation(TSAT), ferritin(SF), C-reactive protein(CRP), albumin(Alb) etc.were collected and recorded before and 1,3,6,12 months after therapy. The dosages of erythropoietin(EPO) at the same period were recorded too. These clinical data were analysis and comparison.　Results　Compared with the drug group, the serum level of iPTH in the operation group was obviously smaller from 1 months, the level of Hb, Hct significantly larger from 6th month and dosage of EPO in the same period were more fewer(P<0.05).After 12 months of treatment, the serum iPTH in operation group and drug group rose to （76.2±65.2）pg/mL and （638.9±233.8）pg/mL respectively, the Hb increased to （115.8±9.3）g/L and （109.5±5.4）g/L respectively, and the dosages of EPO decreased to （94.2±23.7） U/(kg?week) and （153.7±24.8）U/(kg?week) respectively（P<0.05）. The serum levels iron storage index (TSAT, SF), inflammation index (CRP), nutritional index (Alb) between the two groups were no significantly changed before therapy and during the follow-up period in statistics (P>0.05).The incidence of adverse reactions in the operation group was higher than that in the drug group(P<0.01)　Conclusion　This study confirms that treatment of severe SHPT can improve the management of anemia in hemodialysis patients. T-PTX is more effective in correcting sever SHPT and improving anemia than Cinacalcet.

参考文献/References:

[1] Nikodimopoulou M, Liakos S.Secondary hyperparathyroidism and target organs in chronic kidney disease[J].Hippokratia，2011,15(1):33-38.
[2] Schlosser K, Veit JA, Witte S, et al.Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial[J].Trials，2007,8(1):22.
[3] KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J].Kidney Int Suppl，2009(113):S1-130.
[4] 胡玉清, 许树根, 郭明, 等.甲状旁腺全切术加前臂种植术治疗尿毒症继发性甲状旁腺功能亢进25例临床分析[J].中国中西医结合肾病杂志，2014,15(11):978-979.
[5] McMurray J, Parfrey P, Adamson JW, et al.Kidney disease: Improving global outcomes (KDIGO) anemia work group.KDIGO clinical practice guideline for anemia in chronic kidney disease[J].Kidney Int Suppl，2012,2(4):279.
[6] 朱月玲, 胡波, 黄盛玲, 等.西那卡塞治疗继发性甲状旁腺功能亢进症临床应用进展[J].临床肾脏病杂志，2018,18(2):120-123.
[7] 许楠, 刘新杰, 周冬仙, 等.甲状旁腺全切术治疗继发性甲状旁腺功能亢进症35例[J].暨南大学学报(自然科学与医学版)，2014,35(2):182-185.
[8] Mei C, Chen N, Ding X, et al.Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis[J].Hemodial Int，2016,20(4):589-600.
[9] Ketteler M, Block GA, Evenepoel P, et al.Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters[J].Kidney Int，2017，92（1）:26-36
[10] 季大玺.维持性血液透析远期并发症的防治[J].医学研究生学报，2008,21(6):561-563.
[11] Brancaccio D, Cozzolino M, Gallieni M.Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach[J].J Am Soc Nephrol，2004,15（Suppl 1）:S21-24.
[12] Cueff A, Seear R, Dyrda A, et al.Effects of elevated intracellular calcium on the osmotic fragility of human red blood cells[J].Cell Calcium，2010,47(1):29-36.
[13] Sikole A.Pathogenesis of anaemia in hyperparathyroidism[J].Med hypotheses，2000,54(2):236,238.
[14] Bhadada SK, Bhansali A, Ahluwalia J, et al.Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy[J].Clin Endocrinol (Oxf)，2009,70(4):527-532.
[15] Khoury N, Chang J, Gru AA, et al.Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab[J].J Clin Endocrinol Metab，2012,97(9):3051-3055.
[16] 赵光本, 杨宁, 辛竹, 等.甲状旁腺切除术纠正继发性甲状旁腺功能亢进改善肾性贫血的临床研究[J].大连医科大学学报，2013,35(4):352-355.
[17] 余娜.慢性肾脏病碱性磷酸酶与甲状旁腺素相关性分析[J].中国医疗前沿，2012,7(23):43-44.
[18] Adhikary LP, Pokhrel A, Yadava SK, et al.Relation between Serum Intact Parathyroid Hormone Level and Hematocrit in Chronic Kidney Disease Patients[J].Kathmandu Univ Med J (KUMJ)，2015,13(51):220,223.
[19] Chen C, Wu H, Zhong L, et al.Impacts of parathyroidectomy on renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism[J].Int J Clin Exp Med，2015,8(6):9830-9838.
[20] Puccini M, Carpi A, Cupisti A, et al.Total parathyroidectomy without autotransplantation for the treatment of secondary hyperparathyroidism associated with chronic kidney disease: clinical and laboratory long-term follow-up[J].Biomed Pharmacother，2010,64(5):359,362.

相似文献/References:

备注/Memo

备注/Memo:
基金项目：基金项目:南京军区医学科技创新项目（15MS101）
更新日期/Last Update: 2019-03-20